Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
|Slideshows|October 17, 2019
5 Psychopharmacologic Approaches to Treating Tinnitus
Author(s)Zeina Chemali, MD, MPH, Romy Nehme, MD
Tinnitus affects 50 million people in the US and can require urgent medical assistance. It can also cause considerable anxiety and even hallucinations. Reducing symptom intensity is key.
Advertisement
Advertisement
Related to this article
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New research maps an mPFC–zona incerta circuit that drives punishment-resistant binge eating and hints at personalized brain stimulation targets for better treatment.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Review the developments in GLP-1s in 2026.
Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
2
Vol 43, Issue 9 - Interactive
3
Debunking the Top 10 Misleading Claims About Antidepressants
4
What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice
5